1. FDA (Food and Drug Administration). Fact sheet for healthcare providers: emergency use authorization for Paxlovid. Revised April 14, 2022. Available at: https://www.fda.gov/media/155050/download. Accessed 4 June 2022.
2. EMA (European Medicines Agency). Paxlovid. Annex 1. Summary of product characteristics. Updated January 28, 2022. Available at: https://www.ema.europa.eu/en/documents/product-information/paxlovid-epar-product-information_en.pdf. Accessed 26 Feb 2022.
3. COVID-19 Treatment Guidelines Panel. Coronavirus disease 2019 (COVID-19) treatment guidelines. Ritonavir-boosted nirmatrelvir. National Institutes of Health. Updated May 31, 2022. Available at https://www.covid19treatmentguidelines.nih.gov/management/clinical-management/. Accessed 3 June 2022.
4. COVID-19 Treatment Guidelines Panel. Coronavirus disease 2019 (COVID-19) treatment guidelines. Therapeutic management of nonhospitalized adults with COVID-19. Updated April 8, 2022. Available at: https://www.covid19treatmentguidelines.nih.gov/management/clinical-management/nonhospitalized-adults--therapeutic-management/. Accessed 3 June 2022.
5. Hsu A, Granneman GR, Bretz RJ. Ritonavir. Clinical pharmacokinetics and interactions with other anti HIV agents. Clin Pharmacokinet. 1998;35:275–91.